Genome wide association studies (GWAS) have contributed significantly to the 43 understanding of complex disease genetics. However, GWAS only report associated signals 44 and do not necessarily identify culprit genes. As most signals occur in non-coding regions 45 of the genome, it is often challenging to assign genomic variants to the underlying causal 46 mechanism(s). Topologically associating domains (TADs) are primarily cell-type 47 109 An example using Bone Mineral Density GWAS signals is shown. (B) Three hypothetical 110 examples illustrated by a cartoon. The ground truth causal gene is shaded in red. The 111 method-specific selected genes are shaded in blue. The top panel describes a nearest gene 112 approach. The nearest gene in this scenario is not the gene actually impacted by the GWAS 113 SNP. The middle panel describes a window approach. Based either on linkage 114 disequilibrium or an arbitrarily sized window, the scenario does not capture the true gene.
independent genomic regions that define interactome boundaries and can aid in the 48 designation of limits within which an association most likely impacts gene function. We 49 describe and validate a computational method that uses the genic content of TADs to 50 discover candidate genes. Our method, called "TAD_Pathways", performs a Gene 51 Ontology (GO) analysis over genes that reside within TAD boundaries corresponding to 52 GWAS signals for a given trait or disease. We applied our pipeline to the GWAS catalog 53 entries associated with bone mineral density (BMD), identifying 'Skeletal System 54 Development' (Benjamini-Hochberg adjusted p=1.02x10 -5 ) as the top ranked pathway. In 55 many cases, our method implicated a gene other than the nearest gene. Our molecular 56 experiments describe a novel example: ACP2, implicated at the canonical 'ARHGAP1' 57 locus. We found ACP2 to be an important regulator of osteoblast metabolism, whereas 58 ARHGAP1 was not supported. Our results via the example of BMD demonstrate how basic 59 principles of three-dimensional genome organization can define biologically informed 60 association windows. Introduction: 69 GWAS have been applied to over 300 different traits, leading to the discovery of 70 important disease associations 1 . However, assigning signals to causal genes has proven 71 difficult because these signals fall principally within noncoding regions and do not 72 necessarily implicate the nearest gene 2,3 . For example, a signal found in an FTO intron has 73 been shown to physically interact with and lead to the differential expression of other 74 genes, and not FTO itself 4 . Moreover, there is evidence suggesting a type 2 diabetes 75 GWAS association impacting TCF7L2 also influences ACSL5 5 . It remains unclear how 76 pervasive these kinds of associations are, but similar strategies are necessary in order for 77 GWAS to better guide research and precision medicine 6 .
78
Chromatin interaction studies have discovered key genome organization principles 79 including TADs 7 . TADs are genomic regions defined by increased contact frequency, 80 consistency across cell types, and their enrichment of insulator element flanks 8 . Therefore,
81
TADs can be used as boundaries of where non-coding causal variants will most likely 82 impact tissue independent function. 83 We developed a computational approach, called "TAD_Pathways", which uses TADs 84 to determine candidate genes. We validated our method using BMD GWAS 9 . Using our 85 method, we identified ACP2 as a novel regulator of osteoblast metabolism. TAD_Pathways is a computational method that uses TADs to discover candidate genes 90 ( Figure 1A) . Alternative approaches either assign genes based on nearest gene or by an 91 arbitrary or a linkage disequilibrium-based window of several kilobases 10 (Figure 1B) . 92 Here, we use human embryonic stem cell TAD boundaries as reported by Dixon et al. and genes that fall inside TADs implicated with BMD associations 8, 11 . We perform a pathway 95 overrepresentation test 12 for the input TAD genes against Gene Ontology (GO) terms 13 .
96
This determines if the geneset is associated with any term at a higher probability than by 97 chance. We included both experimentally confirmed and computationally inferred genes, 98 which permit the inclusion of putative genes which do not necessarily have literature 99 support, but are predicted computationally. For validation, we consider only the most 100 significantly enriched term, but a user can also select multiple. Our method also supports 101 custom input SNP lists. TAD_Pathways software is available at 102 https://github.com/greenelab/tad_pathways. 
Results:
145 TAD_Pathways reveals candidate genes within phenotype-associated TADs 146 We applied TAD_Pathways to BMD GWAS results derived from replication-requiring 147 journals 9,14-16 . Our method implicated 'Skeletal System Development' as the top ranked 148 pathway (Benjamini-Hochberg adjusted p=1.02x10 -5 ). For full BMD TAD_Pathways refer 149 to Supplementary Table S1 . Many candidates were not the nearest gene to the GWAS 150 signal and several had independent eQTL support ( Supplementary Table S2 ). We targeted the expression of four of these genes in vitro using siRNA and assessed 153 transcriptional knockdown efficiency. Knockdown efficiencies were: TNAP 48.7±9.9% 154 (p=0.141), ARHGAP1 68.7±14.3% (p=0.015), ACP2 48.9±6.4% (p=0.035), BET1L 155 56.4±1.0% (p>0.05) and DEAF1 52.7±9.2% (p=0.021) (Figure 2) . 156 We noted variation across the three controls, with the scrambled siRNA control altering 157 expression of OCN (osteocalcin), IBSP (bone sialoprotein), TNAP and BET1L (p<0.05).
158
Relative to the scrambled siRNA control, OCN was downregulated in all siRNA groups 159 (p<0.05) except for BET1L siRNA (p=0.122). OSX, IBSP and TNAP were not significantly 160 altered by any siRNA treatment (Figure 2) . Treatment with ACP2 siRNA led to a 66.0% reduction in MTT metabolic activity 171 versus the scrambled siRNA control (p=0.012). ARHGAP1 siRNA caused a 38.8% 172 reduction, falling short of statistical significance (p=0.088). siRNA targeted against TNAP, 173 BET1L or DEAF1 did not alter MTT metabolic activity (Figure 3A) . increased Hi-C resolution reduced estimated TAD sizes 19 . Despite our method using larger 202 TADs, thus including more presumably false positive genes, we still identify relevant 203 pathways. Furthermore, the method will likely fail in a disease instigated by aberrant 204 looping. We were also concerned that TAD_Pathways would work only in BMD. Indeed, 205 when we applied TAD_Pathways to Type 2 Diabetes, we also identify several candidate 206 genes that are not the nearest gene (see Supplementary Table S3 ). Moreover, the 207 experimental validation was performed in a simplified in vitro cell culture system lacking 208 organismal complexity, and the cell line selected is tetraploid, which may partially 209 compensate for gene knockdown. While TAD_Pathways identified several candidate genes, 210 we only examined two, and our validation approach does not directly interrogate each SNP.
211
Lastly, one of the investigated GWAS SNPs, rs7932354, located in the ARHGAP1 212 promoter, is an ARHGAP1 eQTL in several tissues as determined by GTEx 20 . However, 213 11 none of these tissues are bone related and our screen did not implicate ARHGAP1 in 214 osteoblast processes.
215
In conclusion, TAD_Pathways can be used as a candidate gene discovery tool that uses 216 chromatin looping to map associations to candidate genes. We also validated our method by 217 implicating ACP2 as a gene involved in BMD determination, which warrants future 218 investigation. We believe TAD_Pathways and algorithms that leverage 3D genomic 219 structure will be poised to discover novel disease features. 
